Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 11/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.46 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736376 | 0.85 | MPO (0.42) | ERBB2EGFRERBB3ERBB4KMT2A | |
| SCHEMBL11961092 | 0.81 | ERBB2 (0.49) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL6961006 | 0.78 | ERBB2 (0.54) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL4798131 | 0.78 | ERBB2 (0.47) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL215985 | 0.78 | ERBB2 (0.50) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL23625170 | 0.78 | LMNA (0.50) | KMT2ALMNAMEN1ALDH1A1TRPA1 | |
| SCHEMBL22184958 | 0.78 | NPBWR1 (0.43) | KMT2ALMNAMEN1ALDH1A1TRPA1 | |
| SCHEMBL13026431 | 0.77 | LMNA (0.42) | LMNAALDH1A1TRPA1PTGS1CACNA1C | |
| SCHEMBL12851559 | 0.77 | ERBB2 (0.46) | ERBB2EGFRERBB3ERBB4KCNH2 | |
| SCHEMBL26343466 | 0.77 | KDM4E (0.42) | KMT2ALMNAMEN1TGFBR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124483-B2 | HER3 ligands and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-09-21 | — | — | US | disclosed |
| US-20200223799-A1 | HER3 LIGANDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-16 | — | — | US | disclosed |
| US-8088766-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ERBB2, GRB2, EGFR | ERBB2 1/4885EGFR 3/4885ERBB3 5/4885 |
| US-11124483-B2 | HER3 ligands and uses thereof | ERBB3, ERBB2, EGFR | ERBB2 2/4885EGFR 3/4885ERBB3 1/4885 |
| US-20200223799-A1 | HER3 LIGANDS AND USES THEREOF | ERBB3, ERBB2, EGFR | ERBB2 2/4885EGFR 3/4885ERBB3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.